Literature DB >> 16517476

Ultrastructural damage in vascular endothelium in rats treated with paclitaxel and doxorubicin.

Deniz Yamaç1, Ciğdem Elmas, Candan Ozoğul, Zuhal Keskil, Ayşe Dursun.   

Abstract

Endothelium is the first physiological barrier between blood and tissues and can be injured by physical or chemical stress, particularly by the drugs used in the cancer therapy. Paclitaxel and doxorubicin are frequently used anticancer drugs and their cardiac side effects are well observed in clinical setting. Their side effects on the endothelium are still not clear enough. There are few investigations assessing the damages elicited by the combination use of chemotherapy agents in animal experimental models. The purpose of this study was to examine and compare the side effects of doxorubicin and paclitaxel on endothelium in vivo. The drugs were administered weekly to rats via intraperitoneal injections singly or in combinations. Lastly, aorta endothelium was examined. The most familiar parts of the aorta endothelium are the nucleus, free ribosomes, Weibel-Palada granules, plasmalemmal vesicles, and clear basement membrane. Examination of the endothelium and the related structures revealed some clear degenerative findings. Notably, administration of a paclitaxel and doxorubicin combinations caused the most dramatic change in ultrastructure, which may disrupt many functions of the endothelium.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517476     DOI: 10.1080/01913120500406335

Source DB:  PubMed          Journal:  Ultrastruct Pathol        ISSN: 0191-3123            Impact factor:   1.094


  8 in total

1.  Dynamic contrast enhanced MRI detects changes in vascular transport rate constants following treatment with thermally-sensitive liposomal doxorubicin.

Authors:  Brett Z Fite; Azadeh Kheirolomoom; Josquin L Foiret; Jai W Seo; Lisa M Mahakian; Elizabeth S Ingham; Sarah M Tam; Alexander D Borowsky; Fitz-Roy E Curry; Katherine W Ferrara
Journal:  J Control Release       Date:  2017-04-07       Impact factor: 9.776

Review 2.  Cardiac toxicity: old and new issues in anti-cancer drugs.

Authors:  M Sereno; A Brunello; A Chiappori; J Barriuso; E Casado; C Belda; J de Castro; J Feliu; M González-Barón
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

Review 3.  The tell-tale heart: molecular and cellular responses to childhood anthracycline exposure.

Authors:  Merry L Lindsey; Richard A Lange; Helen Parsons; Thomas Andrews; Gregory J Aune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-09-12       Impact factor: 4.733

4.  Tissue factor expressed by circulating cancer cell-derived microparticles drastically increases the incidence of deep vein thrombosis in mice.

Authors:  G M Thomas; A Brill; S Mezouar; L Crescence; M Gallant; C Dubois; D D Wagner
Journal:  J Thromb Haemost       Date:  2015-06-08       Impact factor: 5.824

5.  In vivo bioimaging as a novel strategy to detect doxorubicin-induced damage to gonadal blood vessels.

Authors:  Hadas Bar-Joseph; Irit Ben-Aharon; Moran Tzabari; Galia Tsarfaty; Salomon M Stemmer; Ruth Shalgi
Journal:  PLoS One       Date:  2011-09-09       Impact factor: 3.240

6.  Doxorubicin-induced vascular toxicity--targeting potential pathways may reduce procoagulant activity.

Authors:  Irit Ben Aharon; Hadas Bar Joseph; Moran Tzabari; Boris Shenkman; Nahid Farzam; Mattan Levi; Ruth Shalgi; Salomon M Stemmer; Naphtali Savion
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

7.  Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats.

Authors:  Jae-Sun Uhm; Woo-Baek Chung; Jung-Sook Yoon; Yong-Seog Oh; Ho-Joong Youn
Journal:  Clin Hypertens       Date:  2014-09-25

8.  Grape-Derived Polyphenols Prevent Doxorubicin-Induced Blunted EDH-Mediated Relaxations in the Rat Mesenteric Artery: Role of ROS and Angiotensin II.

Authors:  Noureddine Idris-Khodja; Paola Di Marco; Mona Farhat; Bernard Geny; Valérie B Schini-Kerth
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-28       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.